Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

CAMBIUM BIO LIMITED Director's Dealing 2020

Nov 18, 2020

64666_rns_2020-11-18_ef6ea8f9-bb4d-4aeb-860a-36c40804dbc9.pdf

Director's Dealing

Open in viewer

Opens in your device viewer

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Regeneus Ltd

ABN 13 127 035 358

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director Graham Vesey
Date of last notice 3rdSeptember 2019

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest Direct and Indirect
Nature of indirect interest(including registered holder)Note: Provide details of the circumstances giving rise to the relevantinterest. Citicorp Nominees Pty Limited as nomineefor Graham Vesey
Date of change 13thNovember 2020
No. of securities held prior to change 15,879,968 fully paid ordinary shares
Class Fully paid ordinary shares
Number acquired 1,029,500 unlisted options - exercisable at$0.14 per share and expiring 31 August2025
Number disposed Nil
Value/ConsiderationNote: If consideration is non-cash, provide details and estimatedvaluation Nil – issue of options under employeeincentive scheme. Estimated value ofunlisted options is $115,088
No. of securities held after change Indirect:15,879,968 fully paid ordinary sharesDirect:1,029,500 unlisted options - exercisable at$0.14 per share and expiring 31 August2025
  • See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Nature of change Issue of unlisted options under Regeneus’ Example: on-market trade, off-market trade, exercise of options, issue Option Share Trust Plan of securities under dividend reinvestment plan, participation in buyback

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

==> picture [434 x 320] intentionally omitted <==

----- Start of picture text ----- Detail of contractNature of interestName of registered holder(if issued securities)Date of changeNo. and class of securities to whichinterest related prior to changeNote: Details are only required for a contract inrelation to which the interest has changedInterest acquiredInterest disposedValue/ConsiderationNote: If consideration is non-cash, provide detailsand an estimated valuationInterest after change----- End of picture text -----

Part 3 –[+] Closed period

Were the interests in the securities or contracts detailed above traded during a[+] closed period where prior written clearance was required? If so, was prior written clearance provided to allow the trade to proceed during this period? If prior written clearance was provided, on what date was this provided?

  • See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011